



Global Health Bytes webinar

Wednesday 19 February 2020, 4.00-4.30 pm NZDT

Dunedin: Room AVC2, Disability Information & Support, Student Learning Centre Offices
(Central Library/Information Services Building), Albany Street

Remote participation by Zoom:

<https://otago.zoom.us/j/486443663?pwd=WGgyUkEyQm13djIPRDRhWFVmWUZZUT09</h4>>

Password: 303183

Preventive TB treatment in people with Diabetes – a new global strategy

Prof Philip Hill, Co-Director, Otago Global Health Institute

Tuberculosis (TB) affects more than 10 million people annually. In addition, it is estimated that one quarter of the world's population have latent TB infection (LTBI), of whom 5-10% will go on to develop TB at some stage in their lifetime. It is now recognized that the vast global reservoir of LTBI needs to be addressed for there to be any chance of TB elimination.

Two high risk groups - child contacts of a TB case and people living with HIV - are already targeted worldwide for preventive treatment of LTBI. However, they account for a very small proportion of the global LTBI reservoir. While there are significant operational challenges to consider, a clear and urgent direction for global TB control towards 'ending TB' is for expansion of preventive treatment strategies. An obvious next step is to target other high-risk groups for preventive treatment of LTBI. One such group, in whom preventive treatment is not yet recommended globally, is people with Diabetes Mellitus (DM) in TB-endemic countries.

Otago researchers are playing a leadership role in a 5M Euro EDCTP project to conduct the world's first trial of preventive treatment in people with DM. This is a multi-centre, randomised (1:1), double blind placebo-controlled trial of rifapentine and isoniazid given once weekly for 12 weeks (3HP) to prevent TB disease in people with DM (PROTID-Africa). Approximately 7000-8000 adults with DM enrolled in DM care in Tanzania and the Uganda will be screened for LTBI; 3000 LTBI-positive individuals will be randomised to 3HP or placebo. The primary outcome measure is the incidence rate of probable or definite TB over 24 months of follow-up. Secondary outcome measures include: treatment completion, adverse events, possible, probable or definite TB; probable or definite TB or death in ≥ 24 months follow-up; and mortality. This Global Health bytes seminar will describe this trial, including the issues faced in its design and implementation.

Instructions for attendees

You will need Internet access as well as speakers on your computer. Each Global Health Bytes webinar will be approximately ½ hour in duration.

1. To join a webinar:

Click on the Zoom link from from PC, Mac, iOS or Android:

<https://otago.zoom.us/j/486443663?pwd=WGgyUkEyQm13djIPRDRhWFVmWUZZUT09</h4>>

Password: 303183

The guest speaker will present their talk, and you will be able to ask questions using the *Chat* function in Zoom. The speaker will respond to questions either verbally, or using Chat. *Please note - this is a webinar and you will not be able to turn your video or microphone on, you are welcome to send questions and chat messages instead.*

2. Using the Chat

1. Attendees will ask questions using the Chat function. In your controls at the bottom window, click **Chat**.

The *Chat* window will open on the right side of your screen if you are not in full screen mode. If you are full screen mode, it will open in a window that you can move around your screen. *Chat* will be in the controls at the bottom of your screen.

3. Type your message and press **Enter** to send it.
4. You can also select who you would like to send the message to by clicking on the drop down next to **To**:
 - When you receive a *Chat* message, you will receive a notification at the bottom of your screen if you do not currently have the Chat window open.

The meeting will be recorded and available through OGHI (web and Facebook links will be posted). It will be part of an archive of meetings which can be accessed via the web. By participating in the *OGHI Global Health Bytes*, you agree to the webinar being recorded and available online.

For any questions or help with Zoom, please contact eConferencing on econferencing@otago.ac.nz or call +64 3 479 8440 during normal work hours (8:30am – 5:00pm NZ time)